CN119157997A - 治疗自身免疫相关疾病的治疗性肽和方法 - Google Patents

治疗自身免疫相关疾病的治疗性肽和方法 Download PDF

Info

Publication number
CN119157997A
CN119157997A CN202411324616.4A CN202411324616A CN119157997A CN 119157997 A CN119157997 A CN 119157997A CN 202411324616 A CN202411324616 A CN 202411324616A CN 119157997 A CN119157997 A CN 119157997A
Authority
CN
China
Prior art keywords
peptide
seq
cells
protein
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411324616.4A
Other languages
English (en)
Chinese (zh)
Inventor
D·H·小瓦格纳
M·G·尤斯曼
C·W·亨利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Op T Co ltd
Original Assignee
Op T Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/184,129 external-priority patent/US20190194290A1/en
Application filed by Op T Co ltd filed Critical Op T Co ltd
Publication of CN119157997A publication Critical patent/CN119157997A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
CN202411324616.4A 2018-01-05 2019-01-04 治疗自身免疫相关疾病的治疗性肽和方法 Pending CN119157997A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862614262P 2018-01-05 2018-01-05
US62/614,262 2018-01-05
US16/184,129 2018-11-08
US16/184,129 US20190194290A1 (en) 2010-10-19 2018-11-08 Methods for preventing, modulating and/or reducing cardiovascular disease
CN201980017176.9A CN111801110B (zh) 2018-01-05 2019-01-04 治疗性自体相关疾病的治疗性肽和方法
PCT/US2019/012425 WO2019136307A1 (en) 2018-01-05 2019-01-04 Therapeutic peptides and methods for treating autoimmune related disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980017176.9A Division CN111801110B (zh) 2018-01-05 2019-01-04 治疗性自体相关疾病的治疗性肽和方法

Publications (1)

Publication Number Publication Date
CN119157997A true CN119157997A (zh) 2024-12-20

Family

ID=67144298

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411324616.4A Pending CN119157997A (zh) 2018-01-05 2019-01-04 治疗自身免疫相关疾病的治疗性肽和方法
CN201980017176.9A Active CN111801110B (zh) 2018-01-05 2019-01-04 治疗性自体相关疾病的治疗性肽和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980017176.9A Active CN111801110B (zh) 2018-01-05 2019-01-04 治疗性自体相关疾病的治疗性肽和方法

Country Status (9)

Country Link
EP (1) EP3735260B1 (https=)
JP (2) JP7511242B2 (https=)
CN (2) CN119157997A (https=)
AU (1) AU2019205328B2 (https=)
BR (1) BR112020013716A2 (https=)
CA (1) CA3086193A1 (https=)
MX (1) MX2020007081A (https=)
SG (1) SG11202006494VA (https=)
WO (1) WO2019136307A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190263888A1 (en) 2010-10-19 2019-08-29 Op-T Llc Therapeutic peptides and methods for treating autoimmune related disease
ES2957957T3 (es) 2010-10-19 2024-01-30 Op T Llc Péptidos para modular la actividad de linfocitos T y usos de los mismos
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
JP2022540731A (ja) * 2019-07-12 2022-09-16 オーピー－ティー エルエルシー ペプチドおよび疾患の治療方法
EP4135742A2 (en) * 2020-04-17 2023-02-22 Op-T Llc Bioactive peptides and methods of use thereof
WO2021231898A2 (en) * 2020-05-14 2021-11-18 Op-T Llc Nanoparticle compositions and uses thereof
WO2022036495A1 (en) * 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
CN115807071B (zh) * 2022-09-02 2025-09-26 宁夏医科大学 检测试剂在制备2型糖尿病伴动脉粥样硬化诊断工具中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
WO2005006949A2 (en) * 2003-07-07 2005-01-27 Wagner David H Methods for predicting development of auto-immune diseases and treatment of same
US7449200B2 (en) * 2006-04-17 2008-11-11 Gp Medical, Inc. Nanoparticles for protein/peptide delivery and delivery means
ES2957957T3 (es) * 2010-10-19 2024-01-30 Op T Llc Péptidos para modular la actividad de linfocitos T y usos de los mismos
JP6285923B2 (ja) * 2012-06-22 2018-02-28 トラスティーズ・オブ・ダートマス・カレッジ 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用
EP3123176A4 (en) * 2014-03-23 2018-04-25 The Regents of the University of Colorado Diagnosis of multiple sclerosis in human and animal subjects

Also Published As

Publication number Publication date
MX2020007081A (es) 2020-10-28
CN111801110B (zh) 2024-10-18
EP3735260B1 (en) 2026-03-04
WO2019136307A1 (en) 2019-07-11
AU2019205328B2 (en) 2025-04-03
EP3735260A1 (en) 2020-11-11
JP2021510174A (ja) 2021-04-15
SG11202006494VA (en) 2020-08-28
CN111801110A (zh) 2020-10-20
CA3086193A1 (en) 2019-07-11
JP7511242B2 (ja) 2024-07-05
BR112020013716A2 (pt) 2020-12-22
EP3735260A4 (en) 2021-12-08
JP2024123100A (ja) 2024-09-10
AU2019205328A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
CN111801110B (zh) 治疗性自体相关疾病的治疗性肽和方法
Gurion et al. Systemic arthritis in children: a review of clinical presentation and treatment
US11130795B2 (en) CD154 peptides and methods of inhibiting CD40 interactions with CD154
US12428465B2 (en) Therapeutic peptides and methods for treating type 2 diabetes
US8187596B1 (en) Method of treating asthma or allergy by administering an IL-33 receptor antibody
Kolly et al. Inflammatory role of ASC in antigen-induced arthritis is independent of caspase-1, NALP-3, and IPAF
JP2025116861A (ja) ペプチドおよび疾患の治療方法
JP2014513289A (ja) ＩＦＮβに対する治療応答性を予測するバイオマーカーおよびその使用
US20200072837A1 (en) Methods for preventing, modulating and/or reducing cardiovascular disease
US20190194290A1 (en) Methods for preventing, modulating and/or reducing cardiovascular disease
EP3706799B1 (en) Peptide for preventing, modulating and/or reducing cardiovascular disease
CN114828890A (zh) 使用了干细胞迁移剂的糖尿病治疗
US20020137107A1 (en) Method for identifying agents which modulate chemokine "MEC"-induced functions of CCR3 and/or CCR10
HK40095385A (en) Peptides for modulating t-cell activity and uses thereof
EP1680499A2 (en) Modulation of angiogenesis by bartonella henselae
HK40073293A (en) Diabetes therapy targeting abnormal stem cells
CN114828891A (zh) 以异常干细胞为靶标的糖尿病治疗
JPH11185A (ja) Ａｔｇ−１１２０（ａｉｆ−１−デルタ）、ａｉｆ−１／ｒｃ−９の新規スプライス変種

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination